blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2882421

EP2882421 - LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.04.2023
Database last updated on 20.12.2024
FormerThe patent has been granted
Status updated on  29.04.2022
FormerGrant of patent is intended
Status updated on  14.12.2021
FormerExamination is in progress
Status updated on  12.10.2021
FormerGrant of patent is intended
Status updated on  07.06.2021
FormerExamination is in progress
Status updated on  26.05.2017
Most recent event   Tooltip15.11.2024Change - lapse in a contracting state
Updated state(s): BG		published on 18.12.2024  [2024/51]
Applicant(s)For all designated states
Versantis AG
Technoparkstrasse 1
8005 Zurich / CH
[2023/08]
Former [2022/22]For all designated states
ETH Zurich
ETH Transfer
Raemistrasse 101
8092 Zürich / CH
Former [2015/25]For all designated states
ETH Zurich
ETH Transfer Raemistrasse 101
8092 Zürich / CH
Inventor(s)01 / LEROUX, Jean-Christophe
In der Sommerau 8
CH-8053 Zürich / CH
02 / FORSTER, Vincent
Dorfstrasse 51
CH-8037 Zürich / CH
 [2022/09]
Former [2015/25]01 / LEROUX, Jean-Christophe
In der Sommerau 8
CH-8053 Zürich / CH
02 / FORSTER, Vincent
Culmannstrasse 64
CH-8006 Zürich / CH
Representative(s)LLR
2, rue Jean Lantier
75001 Paris / FR
[N/P]
Former [2022/22]LLR
11 boulevard de Sébastopol
75001 Paris / FR
Former [2015/25]Kasche, André
Kasche & Partner AG
Resirain 1
8125 Zollikerberg / CH
Application number, filing date13745798.206.08.2013
[2022/22]
WO2013EP02352
Priority number, dateEP2012000579609.08.2012         Original published format: EP 12005796
[2015/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014023421
Date:13.02.2014
Language:EN
[2014/07]
Type: A1 Application with search report 
No.:EP2882421
Date:17.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 13.02.2014 takes the place of the publication of the European patent application.
[2015/25]
Type: B1 Patent specification 
No.:EP2882421
Date:01.06.2022
Language:EN
[2022/22]
Search report(s)International search report - published on:EP13.02.2014
ClassificationIPC:A61K9/127, A61P7/08, A61M1/28, A61P3/00, A61P7/00, A61P19/06, A61P39/00, A61P39/02
[2021/23]
CPC:
A61K9/127 (EP,KR,RU,US); A61K9/1271 (EP,KR,US); A61K9/1272 (EP,KR,US);
A61K9/1273 (EP,KR,US); A61M1/287 (EP,US); A61P19/06 (EP);
A61P3/00 (EP); A61P39/00 (EP); A61P39/02 (EP);
A61P7/00 (EP); A61P7/08 (EP,KR); A61K2121/00 (RU) (-)
Former IPC [2015/25]A61K9/127, A61P7/08
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/25]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:LIPOSOMENZUSAMMENSETZUNG FÜR PERITONEALDIALYSE[2015/25]
English:LIPOSOME COMPOSITION FOR USE IN PERITONEAL DIALYSIS[2015/25]
French:COMPOSITION DE LIPOSOME DESTINÉE À ÊTRE UTILISÉE DANS UNE DIALYSE PÉRITONÉALE[2015/25]
Entry into regional phase27.01.2015National basic fee paid 
27.01.2015Designation fee(s) paid 
27.01.2015Examination fee paid 
Examination procedure27.01.2015Examination requested  [2015/25]
24.08.2015Amendment by applicant (claims and/or description)
26.05.2017Despatch of a communication from the examining division (Time limit: M04)
28.06.2017Reply to a communication from the examining division
07.06.2019Despatch of a communication from the examining division (Time limit: M06)
30.11.2019Reply to a communication from the examining division
28.04.2020Despatch of a communication from the examining division (Time limit: M04)
16.06.2020Reply to a communication from the examining division
08.06.2021Communication of intention to grant the patent
12.10.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.12.2021Communication of intention to grant the patent
22.03.2022Receipt of the translation of the claim(s)
22.04.2022Fee for grant paid
22.04.2022Fee for publishing/printing paid
Divisional application(s)EP22172208.5  / EP4062905
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.05.2017
Opposition(s)02.03.2023No opposition filed within time limit [2023/19]
Fees paidRenewal fee
27.07.2015Renewal fee patent year 03
29.07.2016Renewal fee patent year 04
07.08.2017Renewal fee patent year 05
07.06.2018Renewal fee patent year 06
30.08.2019Renewal fee patent year 07
31.08.2020Renewal fee patent year 08
31.08.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.08.2013
AL01.06.2022
AT01.06.2022
BG01.06.2022
CY01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
MK01.06.2022
MT01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
GR02.09.2022
IS01.10.2022
[2024/51]
Former [2024/41]HU06.08.2013
AL01.06.2022
AT01.06.2022
CY01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
MK01.06.2022
MT01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2024/27]HU06.08.2013
AL01.06.2022
AT01.06.2022
CY01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
MK01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2024/20]HU06.08.2013
AL01.06.2022
AT01.06.2022
CY01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2024/18]HU06.08.2013
AL01.06.2022
AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/25]AL01.06.2022
AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SI01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/21]AL01.06.2022
AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SK01.06.2022
SM01.06.2022
LU06.08.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/17]AL01.06.2022
AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SK01.06.2022
SM01.06.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/16]AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
MC01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SK01.06.2022
SM01.06.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/12]AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SK01.06.2022
SM01.06.2022
BG01.09.2022
GR02.09.2022
IS01.10.2022
Former [2023/09]AT01.06.2022
CZ01.06.2022
EE01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
PL01.06.2022
RO01.06.2022
RS01.06.2022
SK01.06.2022
SM01.06.2022
BG01.09.2022
GR02.09.2022
Former [2023/07]AT01.06.2022
FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
PL01.06.2022
RS01.06.2022
BG01.09.2022
GR02.09.2022
Former [2022/50]FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
PL01.06.2022
RS01.06.2022
BG01.09.2022
GR02.09.2022
Former [2022/49]FI01.06.2022
HR01.06.2022
LT01.06.2022
LV01.06.2022
BG01.09.2022
GR02.09.2022
Former [2022/47]FI01.06.2022
LT01.06.2022
Cited inInternational search[YA]US2004208922  (MEHLHORN ROLF JOACHIM [US]) [Y] 1-7,9-12 * page 2, paragraph 0016 * * page 3, paragraphs 0023, 0025 - page 4, paragraph 0030 *[A] 8;
 [YDA]  - VINCENT FORSTER ET AL, "Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging liposomes", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 33, no. 13, doi:10.1016/J.BIOMATERIALS.2012.01.042, ISSN 0142-9612, (20120211), pages 3578 - 3585, (20120124), XP028461961 [YD] 1-7,9-12 * page 3579, column r, paragraph 2.1. - page 3581, paragraph 2.2.; figure 2 * [A] 8

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2012.01.042
 [YA]  - STEIN O ET AL, "Cholesterol removal by peritoneal lavage with phospholipid-HDL apoprotein mixtures in hypercholesterolemic hamsters", BIOCHIMICA ET BIOPHYSICA ACTA - LIPIDS AND LIPID METABOLISM, ELSEVIER SCIENCE BV. AMSTERDAM, NL, vol. 1006, no. 1, ISSN 0005-2760, (19891106), pages 144 - 146, (19891106), XP027222744 [Y] 1-7,9-12 * abstract * * page 144 * * page 145; table - * [A] 8
ExaminationUS2008096185
by applicant   - "Encapsulation of Drugs within Liposomes by pH-Gradient Techniques", FENSKE; CULLIS, Liposome Technology, INFORMA HEALTHCARE, (200609), vol. 11, pages 27 - 50
    - MAYER ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, (1986), vol. 857, pages 123 - 126
    - MADDEN, CHEMISTRY AND PHYSICS OF LIPIDS, (1990), vol. 53, pages 37 - 46
    - VERSCHRAEGEN ET AL., J. CANCER RES. CLIN. ONCOL., (2003), vol. 129, pages 549 - 555
    - PARKER ET AL., CANCER RES., (1981), vol. 41, pages 1311 - 1317
    - SADZUKA ET AL., TOXICOLOGY LETTERS, (2000), vol. 116, pages 51 - 59
    - DADASHZADEH ET AL., JOURNAL OF CONTROLLED RELEASE, (2010), vol. 148, pages 177 - 186
    - MIRAHMADHI ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, (2010), vol. 383, pages 7 - 13
    - HIRANO; HUNT, JOURNAL OF PHARMACEUTICAL SCIENCES, (1985), vol. 74, no. 9, pages 915 - 921
    - JAMATY ET AL., CLINICAL TOXICOLOGY, (2010), vol. 48, pages 1 - 27
    - CAVE; HARVEY, ACADEMIC EMERGENCY MEDICINE, (2009), vol. 16, pages 151 - 156
    - HARVEY ET AL., ACADEMIC EMERGENCY MEDICINE, (2009), vol. 16, pages 815 - 824
    - J.-C. LEROUX, "Like IFE, intravenously administered liposomes are investigated to treat cardiovascular drug intoxication", NATURE BIOTECHNOLOGY, (2007), vol. 2, pages 679 - 864
    - BERTRAND ET AL., ACS NANO, (2010), vol. 4, no. 12, pages 7552 - 7558
    - FORSTER ET AL., BIOMATERIALS, (2012), vol. 33, pages 3578 - 3585
    - AURON; BROPHY, PEDIATR. NEPHROL., (2012), vol. 27, pages 207 - 222
    - CLAY; HAINLINE, CHEST, OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS, (2007), pages 1368 - 1378
    - ARBEITER ET AL., NEPHROL. DIAL. TRANSPLANT., (2010), vol. 25, pages 1257 - 1265
    - PELA ET AL., PEDIATR. NEPHROL., (2008), vol. 23, pages 163 - 168
    - HOPE M; BALLY M; WEBB G; CULLIS PR, "Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential", BIOCHIM BIOPHYS ACTA, (1985), pages 55 - 65
    - BERTHELOT MPE; VIOLET D'ANILINE, REPERT CHIM APPL, vol. 1, page 284
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.